>Brookings Oregon News, Sports, & Weather | The Curry Coastal Pilot

News Classifieds Web
web powered by Web Search Powered by Google

News arrow News arrow Business arrow BHHS grad invents product that combats affects of altitude

BHHS grad invents product that combats affects of altitude Print E-mail
Written by Marge Woodfin, Pilot staff writer   
August 14, 2010 05:00 am

Lisa Lent, former Brookings Harbor High School student, former flight attendant, and current chief executive and founder of Vitalah LLC, was featured at Chetco Pharmacy and Gifts during the pharmacy’s Customer Appreciation Day Friday

Lent and her sister Stephanie discussed and demonstrated Oxylent, an award-winning nutrition supplement created by Lisa in 2008 after she was diagnosed with pulmonary embolus, multiple clots in her lungs.

Never one to give up easily, according to her mother, Gro Lent, she began her investigation into a way to combat the effects of altitude, dehydration and poor air quality that can create a negative environment in the body and can lead to serious health issues.

According to her mother, Lisa, even as a young girl, was always determined to find answers to problems, and never gave up

And she was determined to find a way for herself and other colleagues to protect their health.

That determination and confidence kept her at it until, with help from a team of health industry leaders, she created Oxylent, a high quality multi-vitamin, with the idea of helping airline employees and constant air travelers.

However, Oxylent proved to be popular with many in other careers, and was rated as one of the top 10 products of the year by Vitamin Retailer, a leading industry publication,

Lisa said that Oxylent, the nutritional supplement she created for those who travel, has become the supplement for everyday life. She noted that it has been incredible to follow the progress of Oxylent.

She said, “Just last week we were in Florida where we trained 500 store owners and employees of The Vitamin Shoppe.”

Oxylent is available at health food stores and retail outlets, as well as online at www.vitalah.com. For more information, call 877-699-5368 or 877 OXYLENT.

 

Business News by Yahoo Finance

  • Economy seen regaining muscle in second quarter
    U.S. economic growth likely regained steam in the second quarter as activity picked up broadly, which would bolster expectations for a stronger performance in the last six months of the year. Gross domestic product likely grew at a 3.0 percent annual rate after shrinking at a 2.9 percent pace in the first quarter, according to a Reuters survey of economists. "I don't think the contraction we saw in the first quarter is reflective of what's truly going on in the economy," said Gus Faucher, senior economist at PNC Financial Services Group in Pittsburgh. Earlier in the second quarter, growth estimates were as high as 4 percent, but they were cut as trade, consumer spending and business investment rebounded from the winter slump by less than expected.
  • Asian shares hit six and a half year high, dollar steady before Fed
    Asian shares touched a six-and-half-year peak on Wednesday and the dollar was steady, with investors waiting for second quarter U.S. growth data as well as a U.S. Federal Reserve meeting that some believe might yield a more hawkish policy outlook. The Fed will not be updating its economic forecasts and Chair Janet Yellen will not hold a news conference following the two-day policy meeting, leaving investors' focus squarely on a statement scheduled to be released at 2 p.m. (18:00 GMT).
  • AstraZeneca buys Almirall lung drugs for up to $2.1 billion
    AstraZeneca (AZN.L) took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's (ALM.MC) lung drugs. The British drugmaker, which resisted a $118 billion takeover attempt by Pfizer (PFE.N) in May, said it would pay an initial $875 million and up to $1.22 billion more if the drugs meet development and sales targets. The tie-up boosts a key therapeutic area for AstraZeneca, whose Chief Executive Pascal Soriot is determined to show his company has a strong independent future. Soriot also struck a clinical trial collaboration with Japan's Kyowa Hakko Kirin (4151.T) for a study that will evaluate a combination of the two companies' drugs in cancer - another important field for AstraZeneca.

Follow Curry Coastal Pilot headlines on Follow Curry Coastal Pilot headlines on Twitter

© Copyright 2001 - 2014 Western Communications, Inc. All rights reserved. By Using this site you agree to our Terms of Use